IP Library Patent Application 12304007
Patent Application
App. No. 12/304,007

COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/304,007
Abstract

3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, 4-(2,6-Dimethylbenzyloxy)-phenylacetic acid, and their pharmaceutically acceptable salts are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

Claims (19)

1 . (canceled)

2 . (canceled)

3 . A method for treating a mammalian subject with a condition selected from the group consisting of insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis comprising administering to the subject an amount of a biologically active agent,

wherein the agent is selected from the group consisting of:

3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid;

4-(2,6-Dimethylbenzyloxy)phenylacetic acid;

and their pharmaceutically acceptable salts.

4 . The method of claim 3 , wherein the subject is a human.

5 . The method of claim 4 , wherein the agent is administered orally in an amount from one milligram to four hundred milligrams per day.

6 . The method of claim 3 , wherein the condition is insulin resistance syndrome or Type II Diabetes.

7 . The method of claim 3 , wherein the treatment reduces a symptom of diabetes or the chances of developing a symptom of diabetes, wherein the symptom is selected from the group consisting of: atherosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration and cataracts, associated with diabetes.

8 . A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and from one milligram to four hundred milligrams of a biologically active agent,

wherein the agent is selected from the group consisting of:

3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid;

4-(2,6-Dimethylbenzyloxy)phenylacetic acid;

and their pharmaceutically acceptable salts.

9 . The pharmaceutical composition of claim 8 in oral dosage form.

10 . A compound, 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, or a pharmaceutically acceptable salt thereof.

11 . A compound, 4-(2,6-Dimethylbenzyloxy)phenylacetic acid, or a pharmaceutically acceptable salt thereof.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jan 21, 2021
From: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
To: WELLSTAT THERAPEUTICS CORPORATION
Reel/Frame 055056/0891 →
SECURITY AGREEMENT Recorded Sep 18, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: PDL BIOPHARMA, INC.
Reel/Frame 031227/0227 →
SECURITY AGREEMENT Recorded Aug 16, 2013
From: WELLSTAT THERAPEUTICS CORPORATION
To: WHITE OAK GLOBAL ADVISORS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 031029/0875 →